Dipeptidyl peptidase

Results: 124



#Item
91INSTITUT NATIONAL D’ASSURANCE MALADIE-INVALIDITE SERVICE DES SOINS DE SANTE Comité d’ évaluation des pratiques médicales en matière de médicaments

INSTITUT NATIONAL D’ASSURANCE MALADIE-INVALIDITE SERVICE DES SOINS DE SANTE Comité d’ évaluation des pratiques médicales en matière de médicaments

Add to Reading List

Source URL: www.inami.fgov.be

Language: English - Date: 2012-12-05 08:42:10
92INSTITUT NATIONAL D’ASSURANCE MALADIE-INVALIDITE SERVICE DES SOINS DE SANTE Comité d’ évaluation des pratiques médicales en matière de médicaments

INSTITUT NATIONAL D’ASSURANCE MALADIE-INVALIDITE SERVICE DES SOINS DE SANTE Comité d’ évaluation des pratiques médicales en matière de médicaments

Add to Reading List

Source URL: www.inami.be

Language: English - Date: 2012-12-05 08:42:10
93INSTITUT NATIONAL D’ASSURANCE MALADIE-INVALIDITE SERVICE DES SOINS DE SANTE Comité d’ évaluation des pratiques médicales en matière de médicaments

INSTITUT NATIONAL D’ASSURANCE MALADIE-INVALIDITE SERVICE DES SOINS DE SANTE Comité d’ évaluation des pratiques médicales en matière de médicaments

Add to Reading List

Source URL: inami.fgov.be

Language: English - Date: 2012-12-05 08:42:10
94INSTITUT NATIONAL D’ASSURANCE MALADIE-INVALIDITE SERVICE DES SOINS DE SANTE Comité d’ évaluation des pratiques médicales en matière de médicaments

INSTITUT NATIONAL D’ASSURANCE MALADIE-INVALIDITE SERVICE DES SOINS DE SANTE Comité d’ évaluation des pratiques médicales en matière de médicaments

Add to Reading List

Source URL: inami.fgov.be

Language: English - Date: 2012-12-05 08:42:10
95Commissioning Support DPP-4 inhibitors (‘Gliptins’): Sitagliptin (Januvia®), Vildagliptin (Galvus®), Saxagliptin (Onglyza®), Linagliptin (Trajenta®▼), Alogliptin (Vipidia®▼)

Commissioning Support DPP-4 inhibitors (‘Gliptins’): Sitagliptin (Januvia®), Vildagliptin (Galvus®), Saxagliptin (Onglyza®), Linagliptin (Trajenta®▼), Alogliptin (Vipidia®▼)

Add to Reading List

Source URL: centreformedicinesoptimisation.co.uk

Language: English - Date: 2014-07-11 10:26:59
96

PDF Document

Add to Reading List

Source URL: www.inami.fgov.be

Language: English - Date: 2012-12-05 08:42:10
97Microsoft PowerPoint - Huang_Nov_16_2007_final_final.ppt

Microsoft PowerPoint - Huang_Nov_16_2007_final_final.ppt

Add to Reading List

Source URL: www.fda.gov

Language: English
98Saxagliptin (Onglyza): A Case Study in  Quality Risk Management Stephen Liebowitz, Ph.D. Group Director Global Regulatory Sciences

Saxagliptin (Onglyza): A Case Study in  Quality Risk Management Stephen Liebowitz, Ph.D. Group Director Global Regulatory Sciences

Add to Reading List

Source URL: www.fda.gov

Language: English
99COMMONWEALTH OF KENTUCKY CABINET FOR HEALTH AND FAMILY SERVICES DEPARTMENT FOR MEDICAID SERVICES PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING Capitol Annex -Room[removed]Capital Avenue Frankfort, Kentucky 40601

COMMONWEALTH OF KENTUCKY CABINET FOR HEALTH AND FAMILY SERVICES DEPARTMENT FOR MEDICAID SERVICES PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING Capitol Annex -Room[removed]Capital Avenue Frankfort, Kentucky 40601

Add to Reading List

Source URL: chfs.ky.gov

Language: English - Date: 2014-08-21 19:36:39
100(2) State of New Product Development (As of July 31, 2013) i. Pipeline in Japan New Molecular Entities Development code (Generic name)

(2) State of New Product Development (As of July 31, 2013) i. Pipeline in Japan New Molecular Entities Development code (Generic name)

Add to Reading List

Source URL: www.mt-pharma.co.jp

Language: English - Date: 2013-07-30 07:47:52